Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâ€™s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Employees

Sector

Biotechnology & Medical Research

More about the company

09-07	Heidelberg Pharma AG Presents New Clinical Data On Lead ATAC Candidate Pamlectabart Tismanitin At International Myeloma Society Annual Meeting	CI
08-28	Heidelberg Pharma And Huadong Medicine Co., Ltd. Sign Additional Collaboration Agreement To Jointly Develop New Antibody Drug Conjugates	CI

Market Cap	116M 134M 110M 99.92M 187M 12.8B 188M 1.31B 506M 6.52B 502M 491M 21.04B	P/E 2026 *	-4.79x	P/E 2027 *	-4.96x
Enterprise Value	109M 125M 102M 93.12M 175M 11.93B 175M 1.22B 472M 6.08B 468M 457M 19.61B	EV / Sales 2026 *	10.9x	EV / Sales 2027 *	7.64x
Free-Float	21%	Yield 2026 *	-	Yield 2027 *	-

09-07	Heidelberg Pharma AG Presents New Clinical Data On Lead ATAC Candidate Pamlectabart Tismanitin At International Myeloma Society Annual Meeting	CI
08-28	Heidelberg Pharma And Huadong Medicine Co., Ltd. Sign Additional Collaboration Agreement To Jointly Develop New Antibody Drug Conjugates	CI
08-27	Heidelberg Pharma Wins Chinese Nod to Start Myeloma Combination Therapy Trial	MT
08-26	Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China	CI
07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-29	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
04-09	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
04-09	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04-04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
03-31	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026
03-26	Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2025	CI

09-07	Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026	EQ
08-31	Heidelberg Pharma and Huadong Medicine Sign Further Cooperation Agreement for the Joint Development of New Antibody-Drug Conjugates	AQ
08-28	Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates	EQ
08-28	Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates	EQ
08-26	Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China	EQ

09-07	Heidelberg Pharma präsentiert neue klinische Daten ihres führenden ATAC-Kandidaten pamlectabart tismanitin auf der Jahrestagung 2026 der International Myeloma Society
08-28	Heidelberg Pharma und Huadong Medicine unterzeichnen weitere Kooperationsvereinbarung zur gemeinsamen Entwicklung neuer Antikörper-Wirkstoff-Konjugate
08-28	Heidelberg Pharma und Huadong Medicine unterzeichnen weitere Kooperationsvereinbarung zur gemeinsamen Entwicklung neuer Antikörper-Wirkstoff-Konjugate
08-26	Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China
07-15	Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf

Wilex AG Share Price Xetra

Stocks

DE0006614720

Biotechnology & Medical Research

Valuation: Wilex AG

Latest news: Wilex AG

Last Transcript: Wilex AG

Analysts' recommendations: Wilex AG

Press Releases: Wilex AG

News in other languages: Wilex AG

Managers and Directors: Wilex AG

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Dong Zhou Liu CEO	Chief Executive Officer	-	23/11/2025
Peter Willinger DFI	Director of Finance/CFO	-	30/04/2026
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	28/02/2021

Director	Title	Age	Since
Georg F. Baur CHM	Chairman	76	13/12/2000
Birgit Kudlek BRD	Director/Board Member	59	24/05/2012
Mathias Hothum BRD	Director/Board Member	58	29/07/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.98%	+5.73%	+54.45%	+113.83%	74.33B
ARGENX SE	-0.39%	+0.02%	+38.84%	+83.28%	62.26B
WUXI BIOLOGICS (CAYMAN) INC.	-0.94%	+6.66%	+30.99%	+23.09%	27.72B
INSMED INCORPORATED	+0.83%	-3.43%	-16.41%	+359.38%	26.42B
BIONTECH SE	+2.02%	-0.87%	+1.85%	-7.92%	24.62B
GENMAB A/S	0.00%	+6.81%	+25.03%	-11.44%	20.72B
PHARMAESSENTIA CORPORATION	-2.54%	-3.36%	+149.64%	+324.48%	15.01B
EXELIXIS, INC.	-1.95%	+1.80%	+42.69%	+165.15%	14.18B
SUMMIT THERAPEUTICS INC.	-5.32%	-8.25%	-10.53%	+823.50%	13.48B
Average	-0.37%	+0.73%	+35.17%	+208.15%	30.97B
Weighted average by Cap.	+0.91%	+2.26%	+36.46%	+149.47%

	2026 *	2027 *
Net sales	10M 11.47M 9.42M 8.58M 16.08M 1.1B 16.1M 113M 43.47M 560M 43.08M 42.13M 1.81B	13M 14.91M 12.24M 11.15M 20.91M 1.43B 20.93M 147M 56.52M 728M 56.01M 54.77M 2.35B
Net income	-24.3M -27.87M -22.89M -20.84M -39.08M -2.67B -39.13M -274M -106M -1.36B -105M -102M -4.39B	-23.5M -26.95M -22.13M -20.16M -37.79M -2.58B -37.84M -265M -102M -1.32B -101M -99M -4.24B
Net Debt	-7.93M -9.09M -7.47M -6.8M -12.75M -871M -12.77M -89.43M -34.47M -444M -34.16M -33.4M -1.43B	-17.24M -19.77M -16.23M -14.78M -27.72M -1.89B -27.75M -194M -74.93M -965M -74.25M -72.61M -3.11B

End-of-day quote Xetra
- ^EUR	-